Tuesday, Aadi Bioscience Inc. (NASDAQ:AADI) announced it will halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating ...

The company halted Phase II trial of its mTOR inhibitor after an independent analysis found that it would not meet the efficacy threshold.

Aadi Bioscience expects that pipeline adjustments and the workforce reduction will extend its cash runway into at least the ...

Tuberous sclerosis complex is a multisystem disorder in which neurologic problems cause the greatest disability. High rates of mental retardation and autism spectrum disorders are associated with ...

The company had been investigating the approved mTOR inhibitor, also known as nab-sirolimus, in the midstage PRECISION1 study in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 ...

It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in ...

“While nab-sirolimus showed monotherapy activity in the study population, the trial fell short of delivering what we believe would be required to support an accelerated approval in the broad ...